Physician profile
John B Costello
NPI 1417062563
$3,769.30
in general payments reported to CMS, 2019-2025
15 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $635 · 2021: $785 · 2022: $535 · 2023: $591 · 2024: $562 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,381.89 | 2019-2025 | Enbrel, Otezla, Repatha |
| Lilly USA, LLC | $598.91 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Biotech, INC. | $393.58 | 2019-2023 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $376.91 | 2019-2024 | Orencia |
| Astrazeneca Pharmaceuticals LP | $259.17 | 2019-2025 | Saphnelo, Farxiga, Breztri |
| Pfizer INC. | $196.17 | 2020-2025 | |
| Novo Nordisk INC | $136.68 | 2019-2023 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $102.40 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $101.42 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $76.85 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $60.33 | 2023-2025 | Edarbi, Edarbi |
| Exact Sciences Corporation | $36.60 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $19.02 | 2021 | |
| Chiesi USA, INC. | $18.38 | 2024 | Kengreal |
| Regeneron Healthcare Solutions, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Costello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.